Article
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
Cancer science - 1 Nov 2009
Ozawa Shigeyuki, Kato Yasumasa, Ito Shin, Komori Reika, Shiiki Naoto, Tsukinoki Keiichi, Ozono Satoru, Maehata Yojiro, Taguchi Takahide, Imagawa-Ishiguro Yukari, Tsukuda Mamoru, Kubota Eiro, Hata Ryu-Ichiro
Abstract excerpt
Clinical efficacy of gefitinib (ZD1839, Iressa), which is an inhibitor specific for epidermal growth factor (EGF) receptor tyrosine kinase, has been shown in non-small-cell lung carcinoma patients with EGF receptor mutations, so these mutations are useful marker(s) to find a responder for the drug. Recent studies have shown that the EGF receptor gene mutation is rare in squamous cell carcinoma in the esophageal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.